Mydecine Innovations Group Inc. (CSE:MYCO)

Market Cap	228.81K
Revenue (ttm)	n/a
Net Income (ttm)	-2.44M
Shares Out	n/a
EPS (ttm)	-0.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	34,014
Average Volume	78,859
Open	0.0050
Previous Close	0.0050
Day's Range	0.0050 - 0.0050
52-Week Range	0.0050 - 0.0200
Beta	2.33
RSI	46.86
Earnings Date	Aug 20, 2025

About CSE:MYCO

Mydecine Innovations Group Inc., a biotechnology company, engages in the research, development, and commercialization of psilocybin products to treat mental health conditions. The company primarily focuses on treating nicotine addiction and post-traumatic stress disorder. Its lead product drug candidates include MYCO-005 a family of psilocin analogs. The company also develops MYCO-006 a family of MDMA analogs and MYCO-007. Mydecine Innovations Group Inc. has a partnership with Applied Pharmaceutical Innovation for pharmaceutical drug discovery,...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2013
• Country: Canada
• Stock Exchange: Canadian Securities Exchange
• Ticker Symbol: MYCO